Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients

[1]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[2]  Isabelle Barillot,et al.  Évaluation par le patient de la toxicité aiguë de la radiothérapie pelvienne selon la Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0) : rêve ou réalité ? , 2010 .

[3]  Cynthia S. Johnson,et al.  A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study , 2007, Supportive Care in Cancer.

[4]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Macciocchi,et al.  A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[8]  J. Koeller,et al.  Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement , 2005, Supportive Care in Cancer.

[9]  G. de Pouvourville,et al.  Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.

[10]  J. Hajdenberg,et al.  Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist , 2003, Cancer.

[11]  R. Labianca,et al.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. M. Walton.  Advances in use of the 5-HT3 receptor antagonists , 2000, Expert opinion on pharmacotherapy.

[13]  P. Hesketh.  Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting , 2000, Cancer investigation.

[14]  E. Perez,et al.  Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  U. Tirelli,et al.  Ondansetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting , 1995 .

[16]  V. Gebbia,et al.  Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial , 1994, Cancer.

[17]  M. Kris,et al.  Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.